UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported) May 29, 2009
A.P.
Pharma, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-33221
|
94-2875566
|
||
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer
Identification
No.)
|
|
123
Saginaw Drive
Redwood
City, CA 94063
|
|
|
(Address
of principal executive offices)
|
(650) 366-2626
Registrant’s
telephone number, including area code
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
|
Item 8.01
|
Other
Events.
|
On May
29, 2009, A.P. Pharma, Inc. (the “Company”) announced that it has implemented a
plan to reduce its work force by approximately 34%, or a total of 11 employees.
The Company expects one-time costs associated with this headcount reduction to
be approximately $350,000, which will be recorded in the second quarter of
2009. The actions are being taken to allow the Company to provide the
resources needed to continue advancing its lead program, APF530, towards
regulatory approval and commercialization.
Forward-Looking
Statements
This
current report contains forward-looking statements, including statements related
to expected costs associated with the headcount reduction and the advancement of
APF530 towards regulatory approval and commercialization. These
forward-looking statements are based on the Company’s current expectations and
involve risks and uncertainties. Actual results and the timing of
events could differ materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which include, without
limitation, risks related to difficulties or delays in seeking or obtaining
regulatory approval and other risks details in the Company’s filings with the
Securities and Exchange Commission, including the Annual Report on Form 10-K for
the year ended December 31, 2008 and periodic reports on Form 10-Q and Form
8-K. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this current
report. All forward-looking statements are qualified in their
entirety by this cautionary statement.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
A.P.
Pharma, Inc.
|
||
|
Date:
June 2, 2009
|
/s/
Ronald J. Prentki
|
|
|
Ronald
J. Prentki
|
||
|
President,
Chief Executive Officer and
Director
|
||